Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 Monotherapy and Combination Therapy in Advanced Renal Cell Carcinoma
NCT07227415Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of PF-08634404 in renal cell carcinoma (RCC), sponsored by Pfizer. Started Feb 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07227415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227415.